07 June 2023

---

ProSomnus presents oral appliance therapy treatment research at national meetings

---

Leaders from ProSomnus, Inc, which provides a leading CPAP alternative for the treatment of obstructive sleep apnea (OSA), recently presented research at the 2023 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting and at the American Thoracic Society (ATS) 2023 International Conference.

According to a news release, the data presented at both meetings demonstrate that ProSomnus’s Precision OAT devices are:

• An efficacious first-line treatment for moderate and severe obstructive sleep apnea, characterized by excellent adherence and patient preference relative to CPAP,
• An efficacious option relative to traditional OAT devices, for all severities of OSA, and
• Associated with significantly fewer adverse event reports than CPAP and hypoglossal nerve stimulation treatments.

In the news release, Dr. John Remmers, MD, chief scientist of ProSomnus, said the growing body of clinical evidence continues to show that Precision Oral Appliance Therapy is more efficacious and even safer than legacy treatment options.

“These particular studies not only demonstrate efficaciousness but additional benefits for patients, such as better adherence and fewer adverse events,” he said. 

Data from the First Line Obstructive Sleep Apnea Treatment Study (FLOSAT) study, a clinical trial comparing the clinical effectiveness of OAT and CPAP were presented at both meetings:

• AADSM: "Comparison of Clinical Effectiveness And Patients’ Preference for Two Non-invasive Treatment Options for Patients Diagnosed with Moderate to Severe Obstructive Sleep Apnea: The FLOSAT Study," named winner of AADSM’s Clinical Excellence Award.
  
  
• ATS: "Oral Appliance Therapy as First-line Treatment Option in Patients Diagnosed With Moderate to Severe Obstructive Sleep Apnea." 

In addition, key findings were also presented in the following posters at AADSM:

• "OAT Device Designs are Not the Same When It Comes to FDA Adverse Event Reports."
• "Adverse Event Reports for Continuous Positive Airway Pressure, Hypoglossal Nerve Stimulation and Oral Appliance Therapy Devices: an FDA MAUDE Database Analysis," named winner of AADSM’s Clinical Research Award.
• "Precision vs. Traditional Oral Appliance Therapy: A Comparison of Efficacy."

At ATS 2023, further data were presented in the following poster:

• "Assessing Precision Oral Appliance Efficacy Using Frequency-Based and Risk-Based Indices."

Len Liptak, CEO of ProSomnus, said in the news release that the data further validates that the company's non-invasive, patient-preferred, precision oral appliance therapy is associated with excellent outcomes for patients with OSA.

About ProSomnus

ProSomnus is a leading CPAP alternative for the treatment of obstructive sleep apnea, a serious medical disease affecting over one billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many government sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.